Evidentic GmbH

🎯𝗔𝗺𝗶𝘃𝗮𝗻𝘁𝗮𝗺𝗮𝗯: 𝗔 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗖𝗼𝗺𝗯𝗮𝘁𝘁𝗶𝗻𝗴 𝗡𝗦𝗖𝗟𝗖🧬   Amivantamab from the original Rybrevant® is a bispecific antibody treating non-small cell lung cancer (NSCLC) 🫁. By simultaneously targeting 🎯 the epidermal growth factor receptor (EGFR) and MET pathways, Amivantamab provides a dual-pronged approach to combatting tumor growth and metastasis. Its unique mechanism of action makes the molecule a valuable tool 🛠️ for researchers studying the complexities of NSCLC and developing innovative treatment strategies 💡.   Visit our online shop 🛒 today to access this essential research compound 🔬 and explore our batch library 📚 with other top-quality clinical-grade molecules from original therapeutics. Evidentic offers global access 🌍, reliable sourcing 🔗, and research benefits 📈. Don't miss the opportunity to advance your cancer research! 🧬   #Amivantamab #Rybrevant #NSCLC #LungCancer #EGFR #METPathways #CancerResearch #Biotechnology #InnovativeTherapies #ClinicalResearch #Evidentic #MolecularResearch #Oncology #ResearchCompounds #GlobalAccess

🧠 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: 𝗔 𝗣𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗦𝘁𝗲𝗽 𝗙𝗼𝗿𝘄𝗮𝗿𝗱   The race to find effective treatments for Alzheimer's disease has produced mixed results. While the FDA has approved Aducanumab (Aduhelm®), Lecanemab (Leqmbi®), and Donanemab (Kisunla®), the European Medicines Agency (EMA) is taking a more cautious approach. ⚖️   Lecanemab (Leqembi®), approved by the FDA in July 2024, has demonstrated potential in slowing cognitive decline in Alzheimer's patients. However, the European Medicines Agency (EMA) rejected its application, citing concerns about the balance between the observed benefits and the risks of serious side effects, such as Amyloid-related imaging abnormalities (ARIA). 🔬   𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗨𝗽𝗱𝗮𝘁𝗲 👍 MHRA Approval: The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Lecanemab, making it available to patients in the UK. 🔄 EMA Re-examination: The company behind Leqembi has requested a re-examination of the EMA's July 2024 decision. This could potentially lead to a different outcome.   𝗡𝗲𝗲𝗱 𝗟𝗲𝗰𝗮𝗻𝗲𝗺𝗮𝗯 𝗳𝗼𝗿 𝗬𝗼𝘂𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵? 🛒 Evidentic is your sourcing specialist for licensed Lecanemab , sourced directly from the original Leqembi®, and other top-quality clinical-grade molecules. 🧬 Check our online shop (link in the comments) and discover the potential of clinical-grade molecules to improve research outcomes!   #Alzheimers #Lecanemab #FDA #EMA #MHRA #Neuroscience #Evidentic #MonoclonalAntibodies #MABs #ClinicalGrade #DrugDevelopment #DrugDiscovery #MedicalResearch #Pharmaceuticals #ResearchandDevelopment

🔍𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗔𝘁𝘁𝗿𝗶𝗯𝘂𝘁𝗲𝘀 (𝗖𝗤𝗔𝘀): 𝗔𝗻𝗮𝗹𝘆𝘁𝗶𝗰𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀📊   Critical Quality Attributes (CQAs) ensure the safety and efficacy of biologic products. We explain how these attributes are identified, assessed for risk, and categorized into product-specific, process-related, and obligatory groups. There are numerous CQAs for clinical-grade products delving into the structure and function of proteins and the examination of excipients.   Dr. Benjamin Müller, CEO and co-founder of the (bio)analytical company Biofidus AG, provides deeper insights in an interview on the significance of CQAs in drug development projects: https://lnkd.in/dbyb5YMY   Read more about the secrets of CQAs in our blog article: https://lnkd.in/dPwjHnqx.   #BiopharmaInsights #CQAs #BiologicQuality #EvidenticBlog #AnalyticalData #BiotechInnovation #Healthcare #QualityMatters #BioTech 🌐🧪📚🚀

🔍𝗙𝗮𝗰𝗶𝗻𝗴 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝗦𝗼𝘂𝗿𝗰𝗶𝗻𝗴 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗥𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀?   No worries, you're in the right place! We're constantly expanding our network to source even the most challenging molecules to provide you with a wider range of licensed molecules, including those approved by the FDA but not yet available in the EU. 🌍   𝗪𝗵𝘆 𝗰𝗵𝗼𝗼𝘀𝗲 𝗘𝘃𝗶𝗱𝗲𝗻𝘁𝗶𝗰? 🌐 Global Reach: Access a wider variety of licensed therapeutic reference standards and biosimilars. 🕒 Time-Saving: Benefit from shorter timelines for faster product-to-market. 🔬 Quality Assurance: Boost the accuracy and reliability of your R&D with clinical-grade molecules. 🆚 Comparative Analysis: Compare EU and US material to identify the best fit for your needs. Ready to accelerate your research? Contact us today to source the therapeutic reference standards you require.   Visit our website (link in the comments) for your access to licensed molecules, biosimilars, and historical batches of original and biosimilar drugs in smaller units. 🧪   #Evidentic #ClinicalGradeMolecules #ResearchAndDevelopment #DrugDevelopment #PharmaInnovation #BiotechInnovation #HealthcareInnovation 🧪🌐💊🔬🔝

🧠 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: 𝗔 𝗖𝗼𝗺𝗽𝗹𝗲𝘅 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝘄𝗶𝘁𝗵 𝗔 𝗖𝗼𝗻𝘁𝗿𝗼𝘃𝗲𝗿𝘀𝗶𝗮𝗹 𝗦𝘁𝗮𝗿𝘁   The race to find effective treatments for Alzheimer's disease has produced mixed results. While the FDA has approved Aducanumab (Aduhelm®), Lecanemab (Leqmbi®), and Donanemab (Kisunla®), the European Medicines Agency (EMA) is taking a more cautious approach. ⚖️   Aducanumab (Aduhelm®), a monoclonal antibody, was approved by the FDA in June 2021 through a controversial accelerated procedure for the treatment of Alzheimer's disease. The decision met with widespread criticism as the drug's efficacy had not been clearly proven.🔬   The EMA rejected the application for approval in December 2021, citing insufficient data and concerns about serious side effects. 🚫   🛒 𝗡𝗲𝗲𝗱 𝗔𝗱𝘂𝗵𝗲𝗹𝗺 𝗳𝗼𝗿 𝗬𝗼𝘂𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵? Evidentic is your sourcing specialist for licensed Aducanumab, sourced directly from the original Aduhelm®, and other top-quality clinical-grade molecules. 🧬 Contact us or visit our website (link in the comments) and discover the potential of clinical-grade molecules to improve research outcomes!   #Alzheimers #Aduhelm #FDA #EMA #Neuroscience #Evidentic #MonoclonalAntibodies #MABs #ClinicalGrade #DrugDevelopment #DrugDiscovery #MedicalResearch #Pharmaceuticals #ResearchandDevelopment

🌟 𝗠𝗲𝗲𝘁 𝗦𝗼𝗳𝗶𝗮, 𝗼𝘂𝗿 𝗴𝗹𝗼𝗯𝗮𝗹 𝗽𝗿𝗼𝗯𝗹𝗲𝗺-𝘀𝗼𝗹𝘃𝗶𝗻𝗴 𝗽𝗼𝘄𝗲𝗿𝗵𝗼𝘂𝘀𝗲 🌐   Originally from Portugal, Sofia brings global expertise and connections to Evidentic 🌍 since 2021. Her diverse background in marketing 📈, operations ⚙️, and projects 📊 makes her a problem-solving whiz 🧠.   Need a molecule sourced? 🧪 Stuck on a project? 🛠️ Sofia's on it! 💼   Her in-depth knowledge across Business Development 💼, Customer Service 🤝, Logistics 🚚, and Marketing 📣 ensures smooth communication and efficient operations.   Think global connector, think Sofia! 🌎   #Evidentic #ResearchAndDevelopment #DrugDevelopment #DrugDiscovery #InterfaceManager #GlobalCitizen #Teamwork | Sofia Araujo

🌟𝗣𝗮𝗻𝗶𝘁𝘂𝗺𝘂𝗺𝗮𝗯: 𝗔 𝗣𝗼𝘄𝗲𝗿𝗳𝘂𝗹 𝗔𝗹𝗹𝘆 𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵🧬   Panitumumab from the original Vectibix® can provide invaluable insights into colorectal cancer research. By targeting 🎯 and inhibiting ❌ the epidermal growth factor receptor (EGFR) pathway, this molecule offers a powerful tool 🛠️ for understanding disease mechanisms and developing innovative therapies 💡.   Visit our online shop 🛒 today to access this essential research compound 🔬 and explore our batch library 📚 with other top-quality clinical-grade molecules from original therapeutics. Evidentic offers global access 🌍, reliable sourcing 🔗, and research benefits 📈. Don't miss the opportunity to advance your cancer research! 🧬   #Panitumumab #Vectibix #ColorectalCancer #CancerResearch #EGFR #TargetedTherapy #ClinicalResearch #Biotechnology #Evidentic #GlobalAccess #InnovativeTherapies #MolecularResearch #Oncology #ResearchCompounds

💊 𝐋𝐨𝐰 𝐢𝐧 𝐒𝐭𝐨𝐜𝐤 𝐑𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝𝐬! 🛒   🧪 In early drug development, researchers deal with some challenges. Don't let the access to licensed molecules be one of them.   If you're in need of small units from licensed drugs, we've got you covered. Take a look at our current selection of rare drug aliquots and see if any of our unique batches align with your research project. Additionally, we introduce the historical batches of the rare molecules that are almost out of stock and cannot be replaced. 📦💊   We encourage you to act quickly before they sell out completely. Check our online shop link in the comments! 🛒🔬   #InnovationInMedicine #ResearchAndDevelopment #ClinicalGradeMolecules #Evidentic #Antibody #mAb #ClinicalGrade #DrugDevelopment #DrugDiscovery

📢 𝗔𝗗𝗖 𝗕𝗮𝗰𝗸 𝗶𝗻 𝘀𝘁𝗼𝗰𝗸: 𝗘𝗻𝗳𝗼𝗿𝘁𝘂𝗺𝗮𝗯 𝘃𝗲𝗱𝗼𝘁𝗶𝗻 🎉 Enfortumab vedotin is revolutionizing cancer treatment by delivering chemotherapy directly to cancer cells 🎯. Targeting the Nectin-4 protein, it offers the potential for better outcomes and expanded treatment options 🌟. Visit our online shop 🛒 to access this innovative ADC and other top-quality clinical-grade molecules (link in the comments). At Evidentic, we provide global access, reliable sourcing, and extensive research benefits! Get licensed molecules in small units or historical batches of original drugs as well as biosimilars in our batch library! 🧬 #CancerResearch #ADC #EnfortumabVedotin #Biotech #Pharmaceuticals #biopharma #drugdevelopment #research #biologics #evidentic #antibody #mab #clinicalgrade #researchanddevelopment #drugdiscovery

𝗡𝗲𝗲𝗱 𝗧𝗼𝗰𝗶𝗹𝗶𝘇𝘂𝗺𝗮𝗯 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗼𝗿 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗿𝗼𝗷𝗲𝗰𝘁? 🔬   Evidentic has you covered! We offer 6 batches of Tocilizumab from the original drug RoActemra®. This vital biologic treats conditions like rheumatoid arthritis and giant cell arteritis by targeting inflammation. 🌟   Looking for other licensed molecules in smaller units or historical batches of original drugs or biosimilars? Explore our batch library (link in the comments)! 🧬   #biopharma #drugdevelopment #research #tocilizumab #biologics #evidentic #antibody #mab #clinicalgrade #researchanddevelopment #drugdiscovery